

Appendix 3.a FLAG-Ida unit costs.

	Details	Figure	Reference
Fludarabine	50mg in 2ml vial	¶¶	All Wales Drug Contract price
Cytarabine	2g in ml vial	¶¶	All Wales Drug Contract price
Idarubicin	5mg in 5ml vial	¶¶	All Wales Drug Contract price
G-CSF	0.5ml syr 480 mcg/ml x 5	¶¶	All Wales Drug Contract price
SB14Z Deliver complex parenteral chemotherapy at first attendance - elective inpatients		£3,024	NHS reference cost ³⁵
SB14Z Deliver complex parenteral chemotherapy at first attendance - day or night unit cost		£493	NHS reference cost ³⁵
SA25K: Acute Myeloid Leukaemia with CC Score 4-5		£379	2024/25 NHS Payment Scheme ⁴⁶
¶¶ commercial in confidence data removed			

Appendix 3.b FLAG-Ida regimen doses and costs.

	Daily dose	Dose per day	Units required per day	Days per cycle	Cost per cycle
Fludarabine*	30mg/m ²	53.7	1	5	¶¶
Cytarabine*	2g/m ²	3.58	2	5	¶¶
Idarubicin*	8mg/m ²	14.32	3	3	¶¶
G-CSF†	5mcg/kg	395	0.4 (2 syr)	7	¶¶
Per cycle medicine cost					¶¶
*dose per day calculated using 1.79 m ² [33]					
† dose per day calculated using the average UK adult weight of 79kg ⁴⁷ .					
¶¶ commercial in confidence data removed					

The administration of FLAG-Ida is calculated with a hospitalisation duration of 20 days, this is informed by clinical experts. The initial SB14Z elective inpatient has a trim point of 5 days, therefore, an additional active therapy cost of 2 days is applied at the SB14Z day or night cost to total the 7 days of treatment. A further 13 days are applied at a cost of SA25Z AML to total the average duration of 20 days. The total cost of administration and hospitalisation for a FLAG-Ida cycle is £8,937. The total cost for a cycle of FLAG-Ida is £10,449.

Appendix 3.c FLAG-Ida administration and hospitalisation costs.

	Cost	Reference
SB14Z Deliver complex parenteral chemotherapy at first attendance - elective inpatients	£3,024	NHS reference cost ³⁵
SB14Z Deliver complex parenteral chemotherapy at first attendance - day or night unit cost	£493	NHS reference cost ³⁵
SA25K: Acute Myeloid Leukaemia with CC Score 4-5	£379	2024/25 NHS Payment Scheme ⁴⁶
Total administration and hospitalisation cost	£8,937	(3024 + (2*493) + (13*379))
¶¶ commercial in confidence data removed		

Appendix 3.d. Adverse event rates, costs and disutilites

	Cost	QALY decrement	Ven Aza	FLAG-Ida	HRG or TA765 reported cost	Reference
Anaemia	£420	0.008	26.0%	30.3%	SA08H	NICE TA 765 ¹⁸
Febrile Neutropenia	£420	0.008	42.0%	36.7%	SA08H	NICE TA 765 ¹⁸
Hypokalaemia	£365	0.010	11.0%	11.0%	303.57	NICE TA 765 ¹⁸
Leukopenia	£1,234	0.008	21.0%	missing	1026.11	NICE TA 765 ¹⁸
Neutropenia	£420	0.008	42.0%	13.8%	SA08H	NICE TA 765 ¹⁸
Neutrophil Count Decreased	£1,234	0.008	missing	11.0%	1026.11	NICE TA 765 ¹⁸
Platelet Count Decreased	£1,234	0.008	missing	24.8%	1026.11	NICE TA 765 ¹⁸
Pneumonia	£216	0.018	20.0%	4.6%	179.96	NICE TA 765 ¹⁸
Thrombocytopenia	£361	0.008	45.0%	16.5%	SA12K	NICE TA 765 ¹⁸
White Blood Cell Count Decreased	£1,234	0.008	missing	17.4%	1026.11	NICE TA 765 ¹⁸
Hypoglycemia	£490	0.013	missing	8.3%	KB04K	NICE TA 642 ³
Total cost			£967	£1,146		

Appendix 3.e. Hematopoietic Stem Cell Transplantation costs

	Cost/figure	Reference / calculation
Matched unrelated donor HSCT	¶¶	WJCC
Sibling donor HSCT	¶¶	WJCC
Activity: Matched unrelated donor HSCT	1099	BSBMT ⁴⁸
Activity: Sibling donor HSCT	520	BSBMT ⁴⁸
Weighted average cost of HSCT	¶¶	
WJCC: Wales Joint Commissioning Committee BSBMT: British Society of Blood and Marrow Transplantation and Cellular Therapy ¶¶¶ commercial in confidence data removed		

Appendix 3.f. Equality in HSCT rates.

	Cost
Venetoclax with azacitidine	¶¶
FLAG-Ida	¶¶
Incremental cost	¶¶
¶¶¶ commercial in confidence data removed	

Appendix 3.g. One way sensitivity analysis: varying number of venetoclax with azacitidine treatment cycles

	40% fewer cycles	20% fewer cycles	10% fewer cycles	baseline	10% more cycles	20% more cycles	40% more cycles
Venetoclax with azacitidine	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶
Incremental cost	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶
¶¶¶ commercial in confidence data removed							

Appendix 3.h. One way sensitivity analysis: varying number of FLAG-Ida hospitalisation days

	10 days	15 days	18 days	baseline (20 days)	22 days	25 days	30 days
FLAG-Ida	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶
Incremental cost	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶	¶¶
¶¶ commercial in confidence data removed							

Appendix 3.i. One way sensitivity analysis: varying number of venetoclax with azacitidine hospitalisation days

	baseline (0 days)	5days hospitalisation	10 days hospitalisation	15 days hospitalisation	20 days hospitalisation
Venetoclax with azacitidine	¶¶	¶¶	¶¶	¶¶	¶¶
Net cost	¶¶	¶¶	¶¶	¶¶	¶¶
¶¶ commercial in confidence data removed					